Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.08 AUD | -3.46% | -2.52% | -5.75% |
29/04 | Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% | MT |
14/03 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.75% | 52Cr | |
-1.26% | 8.95TCr | |
+2.76% | 4.07TCr | |
-9.06% | 3.3TCr | |
+55.32% | 2.47TCr | |
-16.61% | 1.51TCr | |
-9.14% | 1.28TCr | |
-12.11% | 1.18TCr | |
-43.61% | 1.16TCr | |
+7.79% | 890.22Cr |
- Stock Market
- Equities
- CUV Stock
- News Clinuvel Pharmaceuticals Limited
- Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%